Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. (PLX) Revenue
Annual & quarterly revenue history · segment & region breakdown
PLX · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsProtalix BioTherapeutics, Inc. trailing twelve-month (TTM) revenue is $0.08B, a decrease of 1.23% year-over-year from $0.05B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.05B | -$0.00B | -1.23% |
| 2024-12-31 | $0.05B | -$0.01B | -18.47% |
| 2023-12-31 | $0.07B | +$0.02B | +37.48% |
| 2022-12-31 | $0.05B | +$0.01B | +24.22% |
| 2021-12-31 | $0.04B | -$0.02B | -39.03% |
| 2020-12-31 | $0.06B | +$0.01B | +15.00% |
| 2019-12-31 | $0.05B | +$0.02B | +59.73% |
| 2018-12-31 | $0.03B | +$0.01B | +62.44% |
| 2017-12-31 | $0.02B | +$0.01B | +129.13% |
| 2016-12-31 | $0.01B | +$0.00B | +110.79% |
Compare revenue vs peers
BiotechnologyCompare PLX revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Protalix BioTherapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Protalix BioTherapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Protalix BioTherapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
PLX revenue · 4 questionsPLX's trailing twelve-month (TTM) revenue is $0.08B. That is a decrease of 1.23% year-over-year from $0.05B in FY2025.
▸ Source: FMP · Protalix BioTherapeutics, Inc. SEC filings · GAAP · Protalix BioTherapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026